A mutation in the Kirsten rat sarcoma virus transforming protein (KRAS) is the most common genomic driver identified in patients with lung adenocarcinoma. It is a key component of the PI3K and MAPK pathways and is an important regulator of cell proliferation and survival. Tobacco use and ...
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial. Nat Med. 2024;30(2):531-542. 6. Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harbori...
参考资料 [1]Jänne PA, Riely GJ, Gadgeel SM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022 Jun 3. doi: 10.1056/NEJMoa2204619. [2]Negrao MV, Spira AI, Heist RS, et al. Intr...
[5] de Langen AJ, Johnson ML, Mazieres J, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS(G12C) mutation: a randomised, open-label, phase 3 trial. Lancet. 2023. 401(10378): 733-746. [6] Rosell R, Codony-Servat J, Nieto JG, et a...
Mutant KRAS (KM), the most common oncogene in lung cancer (LC), regulates fatty acid (FA) metabolism. However, the role of FA in LC tumorigenesis is still not sufficiently characterized. Here, we show that KMLC has a specific lipid profile, with high triacylglycerides and phosphatidylcholine...
[16]Ferdinandos Skoulidis,etal.STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarc.CANCER DISCOVERY [17]Rebecca Suk Heist,et al.Impact of STK11 mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma...
目前，Lumakras用于非小细胞肺癌的III期临床试验CodeBreak 200正在进行，用于其他携带KRASG12C突变实体瘤的试验也在逐步开展之中。参考文献：[1]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-targeted-therapy-lung-cancer-mutation-previously-considered-resistant-drug [2]. Cox A D,...
2. Johnson ML, et al. Sotorasib versus docetaxel for previously treated non-small cell lung cancer with KRAS G12C mutation: CodeBreaK 200 phase III study. ESMO Congress 2022, LBA10 3. Pasi A. Jänne, et al. New Engl J Med, June 3, 2022. DOI: 10.1056/NEJMoa2204619 ...
[1]Jänne PA, Riely G, Gadgee SM等人。‘Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation’,《N Engl J Med》；2022;386:22. doi:10.1056/NEJMoa2204619.[2]Gadgeel SM, Jänne PA, Spira AI等人。‘KRYSTAL-1: two-year follow-up of adagrasib (MRTX849) ...
[1]Jänne PA, Riely G, Gadgee SM等人。‘Adagrasib in non–small-cell lung cancer harboring a KRASG12C mutation’,《N Engl J Med》;2022;386:22. doi:10.1056/NEJMoa2204619. [2]Gadgeel SM, Jänne PA, Spira AI等人。‘KRYSTAL-1: two-year follow-up of adagrasib (MRTX849) monothe...